Contribute Try STAT+ Today

More than 150 biotech executives and investors took a stand against President Donald Trump’s immigration ban, saying the controversial executive order threatens to undermine a multibillion-dollar industry that relies on a diverse workforce.

Trump’s order — currently suspended while a federal appeals court weighs its merits — barred nationals from seven Muslim-majority nations from entering the US, regardless of their legal status. For biotech, an industry that relies heavily on foreign-born workers, the ban is particularly ominous, executives wrote in a letter to Nature Biotechnology.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • What you really mean is: controversial executive order threatens to undermine a multibillion-dollar industry that relies on a cheap foreign workforce.

Comments are closed.